The largest database of trusted experimental protocols

4 protocols using cd15 pe cy7

1

Immunophenotyping of Neutrophils and Monocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The expression of TLR4, NOX2, and CD11b on the surface of neutrophils and monocytes was evaluated by flow cytometry. Whole blood (200 μL) was treated in 100-μL aliquots incubated at 37°C for 1 h untreated (vehicle) or with 10 ng/mL LPS (SIGMA Life Science, Ireland). Fluorochrome-conjugated monoclonal antibodies (mAb) specific for humans CD14-PerCP, CD15-PECy7, NOX2-FITC, CD66b-Pacific Blue, TLR4-APC (BioLegend®, USA), and CD11b-PE (BD Biosciences, UK) were used. The whole blood was then stained with mAb for 15 min. Red blood cells were lysed with BD lysis buffer. Cells were acquired on a FACSCanto II flow cytometer (BD Bioscience) and analyzed using FlowJo version 10 (Tree Star) (2 (link), 14 (link)). Neutrophils were delineated based on SSC-A and CD66b+ and monocytes based on SSC-A, CD66b, and CD14+ (15 (link), 16 (link)). Monocytes were subdivided into classical, intermediate, and non-classical subtypes. Monocyte subsets were identified as classical: CD14highCD16neg/low; intermediate: CD14highCD16high; non-classical: CD14lowCD16high. A minimum of 10,000 events were collected, and relative expression of antigens was expressed as mean fluorescence intensity (MFI).
+ Open protocol
+ Expand
2

Multiparameter Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Analyses were performed with a FACS Canto II using FACS Diva (BD Biosciences, San Jose, CA, USA) and FlowJo software (TreeStar, Inc., Ashland, OR, USA). The following anti-human antibodies were used: HLA-DR-BV421™, HLA-DR-APC (clone L243), CD80-Alexa647, CD3-APC-Cy7, CD16-PE (clone 3G8), CD15-PE-Cy7, CD15-PerCp-Cy5, CCR3-APC and PerCP-labelled CD14, CD19, CD56, CD123, and CCR3 (all from Biolegend, San Diego, CA), CD4-PE and CD86-PE, CD45-FITC (all from BD Biosciences) and CD3-PerCP and CD8-PerCP (both from eBioscience Inc., San Diego, CA). Viability was determined by using the Fixable Viability Dye eFluor® 780 (eBioscience Inc.). Annexin V-FITC (BD Pharmingen, San Jose, CA, USA) was used to determine cells undergoing apoptosis. For internalization experiments, cells (1x106/ml) were incubated with and without pHrodo-labelled Bet v 1 (1.5 μg/ml) in the presence of GM-CSF/IFN-γ/IL-3.
+ Open protocol
+ Expand
3

Multicolor Flow Cytometry Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following anti-human antibodies were used for staining: CD68-FITC, CD14-PercP-Cy5.5, HLA-DR-APC, CD15-PE-Cy7, CD11b-PErcP-Cy5.5, CD163-BV421, CD14-APC, HLA-DR-PE, CD33-BV421 and PD-L1-BV421 purchased from Biolegend (San Diego, CA), CD11b-PE, CD3-Alexa Fluor 700, CD19-Alexa Fluor 700, CD19-Alexa Fluor 700, CD163-Alexa Fluor 647, CD16-PE-Cy7, CD3-PE, CD19-PE and CD56-PE purchased from BD Biosciences (San Jose, CA), CD14-PE-TR and CD16 PE-TR purchased from Life Technologies (Carlsbad, CA) and CD86-FITC purchased from R&D systems (Minneapolis, MN). CD32-a-FITC Ab was purchased from Stemcell technologies, (Vancouver, Canada). CD-32-B (F-4) was purchased from Santa Cruz Biotechnology, Santa Cruz, CA, and secondary Ab anti-mouse F(ab’)2 was purchased from Thermo fisher scientific (MA, USA).
Intracellular staining of CD68 was performed as follows: PBMC were stained with surface marker antibodies, fixed with fixation/permeabilization buffer (eBioscience), washed, and stained for intracellular antigens in 1X permeabilization buffer. Cells were analyzed on an LSR Fortessa (BD) flow cytometer, and data analyzed using Flow Jo (Treestar, Ashland, OR). Dead cells were excluded based on viability dye staining (Zombie Aqua Fixable Viability Dye, Biolegend).
+ Open protocol
+ Expand
4

Mitochondrial Function Profiling of Leukocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
MitoTracker green (MTG) was used to assess mitochondrial mass of leukocytes. MitoSox red was used to assess mitochondrial superoxide production of leukocytes. Generation of mitochondrial ROS (mtROS) and mitochondrial mass were evaluated using flow cytometry. Whole blood was incubated at 37°C for 1 h untreated (vehicle) or with 10 ng/mL LPS in the presence of MTG dye (1.4 μM) and MitoSox red reagent (15 μM) (ThermoFisher Scientific). Samples were stained with mAb for CD15- PECy7, CD66b-PB (BioLegend®, USA), CD14-APC (Beckman Coulter), and CD16V500 (BD Biosciences, UK) for 15 min. BD lysis buffer was used to lyse red blood cells. Cells were acquired on a BD FACSCanto II flow cytometer. Fluorescence minus one (FMO) controls were used to set gates. Mitochondrial mass and superoxide were quantified based on MFI of MTG and MitoSOX red, respectively (17 (link)). Data were analyzed using FlowJo software version 10.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!